NCT02634723View on ClinicalTrials.gov

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Octocog alfa (recombinant human coagulation factor VIII)

Trial Locations (6)

150070

Institute of Hematology and Oncology, Harbin The First Hospital, Harbin

210019

Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing

250014

Shandong Blood Center, Jinan

310006

Zhejiang Provincial Hospital of TCM/The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou

430074

Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan

450000

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors

lead

Baxalta now part of Shire

INDUSTRY

NCT02634723 - Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A | Biotech Hunter | Biotech Hunter